Evidence map›Paper›PMID 36860668›Full record

ArticleHealth services insights2023

Intravenous Immunoglobulin G (IVIG) Need Assessment Survey Toward Local Manufacturing of IVIG Using a Mini-Pool Plasma Fractionation Technique.

Bisrat Bekele, Zekarias Masresha, Mekdelawit Alemayehu, Berhanu Seyoum, Liya Wassie, Markos Abebe

Abstract read
In one paragraph

Article in Health services insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bisrat BekeleArmauer Hansen Research Institute, Biotechnology and Bioinformatics Directorate, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0001-8773-7467
Zekarias MasreshaArmauer Hansen Research Institute, Biotechnology and Bioinformatics Directorate, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0002-5836-9594
Mekdelawit AlemayehuArmauer Hansen Research Institute, Biotechnology and Bioinformatics Directorate, Addis Ababa, Ethiopia.
Berhanu SeyoumArmauer Hansen Research Institute, Biotechnology and Bioinformatics Directorate, Addis Ababa, Ethiopia.
Liya WassieArmauer Hansen Research Institute, Biotechnology and Bioinformatics Directorate, Addis Ababa, Ethiopia.
Markos AbebeArmauer Hansen Research Institute, Biotechnology and Bioinformatics Directorate, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin therapy has a crucial role in the treatment of primary and secondary immunodeficiencies as well as in a multitude of neurologic, hematologic, infectious, and autoimmune conditions. In the current study, a preliminary pilot scale needs assessment survey was conducted to examine the need for IVIG among patients in Addis Ababa, Ethiopia, and in so doing justify local manufacturing of IVIG products. The survey was performed by administering a structured questionnaire to private and government hospitals, a national blood bank, a regulatory body, and healthcare researchers working in academia and pharmaceutical companies. The questionnaire encompassed demographics and specific IVIG-related questions designed for each institution. Responses supplied in the study provide qualitative data. Our findings indicated that IVIG has been registered by the regulatory body for use in Ethiopia and there is a demand for the product in the country. The study also highlights that patients go as far as to clandestine markets to procure IVIG products at a cheaper price. To impede such illegal routes and make the product readily accessible, a small-scale and low-cost approach such as a mini-pool plasma fractionation technique could be implemented to locally purify and prepare IVIG using plasma collected through the national blood donation program.

Indexed as

Convalescent seraimmunoglobulinimmunotherapyIVIGplasma fractionation

Identifiers

PMID36860668
PMCPMC9969427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.